



NATURAL CAPSULES LIMITED

No. 23, "Trident Towers", 4th Floor, 100 ft. Road, Jayanagar 2nd Block,
Bangalore - 560 011. Ph. 26671571/573, Fax 26671562,
E-mail : Info@naturalcapsules.com / CIN: L85110KA1993PLCO14742



EXTRACT OF STATEMENT OF STANDALONE AND UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2019

(Rs.in Lakhs)

Sl. No.	PARTICULARS	QUARTER ENDED			Year Ended
		30-06-2019	31-03-2019	30-06-2018	31-03-2019
		Un-Audited	Audited	Un-Audited	Audited
1	Revenue from operations & other Income	1,428.36	1,593.00	1,432.73	6,110.00
2	Net Profit from Ordinary activities after tax	35.51	91.00	47.41	192.00
3	Net Profit for the period after tax (after Extraordinary items)	35.51	91.00	47.41	192.00
4	Paid-up Equity Share Capital (Face value of share of Rs.10/- each as on date)	623.27	623.27	623.27	623.27
5	Other Equity			-	4,926.18
6	Earnings Per Share (EPS) (of Rs.10/- each) (Before & after extraordinary item)				
	(a) Basic EPS (in Rs.)	0.57	1.46	0.76	3.08
	(b) Diluted EPS (in Rs.)	0.57	1.46	0.76	3.07

Note:

- The unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 9th Aug 2019. These results have been subjected to Limited review carried out by the Statutory Auditors.
- The unaudited Standalone Financial results for the Quarter and Year ended 30th June 2019 have been prepared above in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules 2016. The above Audited Standalone Financial results are filed with Stock Exchanges under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchange Website.
- Previous years figures have been regrouped wherever necessary.
- The company presently operates in one segment, manufacture of capsules. The company has ventured into setting up manufacturing facilities for Bulk Drugs. The project cost has been estimated at Rs.4590 lacs to be funded by debt of Rs.2750 lacs and internal accruals of Rs.1840 lacs. The company has achieved financial closure. The land has been acquired and the construction activities are in progress. Pilot facilities have been set up in existing factory premises at Bangalore and are fully operational. The company has spent a sum of Rs.549.63 lacs towards this project as on 30-06-2019
- Position of investor complaints for the quarter ended 30th June 2019

Particulars	No. of complaints
Pending as on 01.04.2019	0
Received during the quarter	1
Resolved during the quarter	1
Pending as on 30-06-2019	0

Place : Bangalore
Date : 09-08-2019

Sd/-
Sunil L Mundra
Managing Director
DIN : 00214304